Efinaconazole
- Generic Name
- Efinaconazole
- Brand Names
- Jublia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H22F2N4O
- CAS Number
- 164650-44-6
- Unique Ingredient Identifier
- J82SB7FXWB
- Background
Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.
- Indication
Indicated in the treatment of fungal infection of the nail, known as onychomycosis.
- Associated Conditions
- Onychomycosis
- Associated Therapies
- -
Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT02812771
- Locations
- 🇺🇸
Valeant Site 01, Birmingham, Alabama, United States
🇺🇸Valeant Site 08, Baltimore, Maryland, United States
🇺🇸Valeant Site 06, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath